None (Main subjects with Slightly higher serum triglyceride level (120 to 200 mg/dL))
Conditions
Interventions
Ingestion of supplement containing astaxanthin and trans-resveratrol for 12 weeks
Ingestion of placebo without astaxanthin and trans-resveratrol for 12 weeks
Sponsors
FANCL CORPORATION
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Males and females from 40 to 64 years of age at the time of the informed consent 2) Slightly higher level of serum triglyceride (The main subjects have 120 mg/dL to 199 mg/dL of serum triglyceride level.)
Exclusion criteria
Exclusion criteria: 1) Subjects who have history of hyperlipidemia and have been by treatment hyperlipidemia with present or the last one year 2) Subjects who are under medication or are judged to that medical treatment are necessary by the medical doctor 3) Subjects who have a history of diabetes, liver disease, kidney disease, and/or adrenal cortex disease 4) Subjects who routinely use medicine (including over-the-counter medicine), Food for Specified Health Uses, Food with function claims, health food 5) Subjects who routinely eat fish as main dish for 5 days per a week 6) Subjects with above BMI 30 kg/m^2 7) Subjects with Hormone-responsive disease (e.g., uterine leiomyoma, endometriosis) 8) Subjects who are under dieting (or weight loss) 9) Subjects who are planned to change their life style 10) Subjects who are planned to become pregnant after informed consent for the current study or are pregnant or lactating 11) Subject who have participated in other clinical study within the last one month prior to the current study 12) Subject who are judged as unsuitable for the study by the investigator for other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variations from the baseline of serum triglyceride level | — |
Secondary
| Measure | Time frame |
|---|---|
| Variations from the baseline of adiponectin, high molecular weight adiponectin, inflammation markers (TNF-alpha, high sensitive CRP), non-esterified fatty acid, total cholesterol, LDL-cholesterol, HDL-cholesterol, or nonHDL-cholesterol | — |
Countries
Japan
Contacts
Public ContactYoshiki Shimizu
FANCL CORPORATION Research institute
Outcome results
None listed